The role of lanreotide in the treatment of choroidal neovascularization secondary to age-related macular degeneration: a pilot clinical trial.

Purpose: To evaluate the role of somatostatin in the treatment of subfoveal choroidal neovascularization (CNV).

Methods: Twenty eyes of 20 patients with CNV were included in the study. Patients were randomly allocated to treatment with lanreotide (10 eyes) or placebo (10 eyes).